Ramipril
Appearance
- Wɔatwerɛ nsɛm wei ɛwɔ Asante kasa mu
Ramipril, a Altace ne ɛbinom na wɔtɔn no, yɛ aduro a wɔde hwɛ mogyaborosoɔ,akomayareɛ, ne sawa mu yareɛ.[1] [2]Wɔtumi de di dwuma sɛ akwansideɛ aduro wɔ wɔn wɔadi boro mfeɛ aduonunum sɛdeɛ ɛbɛyɛ a wɔnya akomayareɛ, nnwodwoɔ anaa sɛ owuo wɔ nnipa a wɔwɔ yareɛ bi te sɛ asikyireyareɛ ne wɔn a wɔwɔ yareɛ binom.
Yareɛ A Wɔde Sa
[sesa]Yareɛ a wɔde sa no bi ne:
- Mogyaborosoɔ (Hypertension)
- Akoma a ɛntumi nyɛ adwuma yie
- Nnipa a wɔwɔ akomayareɛ
- Ɛyɛ hu wɔ wɔn a wɔadi mfeɛ boro aduonunum: wɔde si akomayareɛ ano,nnwodwoɔ, owuo.
Nsunsuansoɔ
[sesa]- Awosoɔ
- Ɛwa
- Anisobiri ne tipaeɛ ɛsiane mogya a ɛnni nipadua no mu nti.
- Ɔbrɛ, ɛnkanka berɛ a worenyini no
- Anohoyaa, berɛ a worenyini no
- Abofono
- Wobɛ bu ahwe fam
- Nkekaeɛ ho mpopoeɛ (ɛbi te sɛ, ahoɔhyeɛ wo hanam bɛyɛ wo nwunu,ne menemkuro a ɛbɛba atoatoaso).
- Wo koko bɛyɛ wo ya
Beaeɛ A Menyaa Mmoa Firiiɛ
[sesa]- ↑ Heart Outcomes Prevention Evaluation Study Investigators, S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais (2000-01-20), "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients", The New England Journal of Medicine, vol. 342, no. 3, pp. 145–153, doi:10.1056/NEJM200001203420301, ISSN 0028-4793, PMID 10639539, retrieved 2024-08-26
{{citation}}
: CS1 maint: multiple names: authors list (link) - ↑ "Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy", The Lancet (in English), vol. 355, no. 9200, pp. 253–259, 2000-01, doi:10.1016/S0140-6736(99)12323-7, retrieved 2024-08-26
{{citation}}
: Check date values in:|date=
(help)